AFFiRiS AG is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for chronic diseases through its proprietary Specific Active Immunotherapy (SAIT) platform. The cornerstone of their approach is the AFFITOME® technology, which enables the identification of specific proteins involved in disease progression. By determining the relevant amino acid sequences, or epitopes, that the immune system recognizes, AFFiRiS creates modified sequences called AFFITOPEs®. These are designed to stimulate a targeted immune response, encouraging the body to produce antibodies against pathogenic proteins, thereby aiming to halt or reverse disease progression.

The SAIT approach offers several advantages, including the potential for less frequent dosing regimens, which can improve patient adherence to treatment. The AFFITOPE® formulations are administered via subcutaneous injection, promoting a long-lasting immune response that is both specific and well-tolerated. AFFiRiS is actively advancing its pipeline of immunotherapies, with several candidates ready to enter Phase II clinical trials, reflecting their commitment to addressing unmet medical needs in chronic disease management.

Austria

We are a clinical-stage biotechnology company that strives to challenge established treatment options for neurodegenerative diseases in order to preserve the quality of life of patients.

AFFiRiS AG

Company Details